LIQUID PHARMACEUTICAL COMPOSITIONS OF BACLOFEN FOR ORAL ADMINISTRATION
Liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof are described. More specifically, stable liquid pharmaceutical compositions of baclofen at concentrations of 2 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions are suitable for oral administration, and stable at pH ranges of 3-8 over a variety of storage conditions, including long-term storage for extended periods of time. Various methods for preparing stable liquid pharmaceutical compositions of baclofen are described. Methods of treating spasticity using the inventive pharmaceutical compositions are also provided.
1 . A stable pharmaceutical solution comprising:
a. a therapeutically effective amount of baclofen;
b. at least one crystallization inhibitor; and
c. at least one pharmaceutically acceptable liquid vehicle;
wherein a concentration of the baclofen is 2 mg/mL or more;
wherein the crystallization inhibitor is selected from the group consisting of polyvinylpyrrolidone (PVP), hydroxyethyl cellulose (HEC), xylitol, and mixtures thereof,
wherein the solution is in the form of a ready-to-use or a ready-to-administer stable solution that is suitable for oral administration to a subject in need thereof, and
wherein the solution does not contain cyclodextrin or cyclodextrin derivatives.
2 . A stable oral pharmaceutical solution according to claim 1 , wherein a level of 4-(4-chlorophenyl)-2-pyrrolidinone is less than about 2% (w/w) as measured by HPLC when stored for 3 months at 40° C./75% RH.
3 . The stable oral pharmaceutical solution according to claim 1 , wherein the baclofen is present at a concentration of about 5 mg/mL to about 10 mg/mL.
4 . The stable pharmaceutical solution according to claim 1 , wherein the baclofen is present at a concentration of about 5 mg/mL.
5 . The stable pharmaceutical solution according to claim 1 , wherein the crystallization inhibitor is present in an amount ranging from about 1 mg/mL to about 200 mg/mL.
6 . The stable pharmaceutical solution according to claim 1 , wherein the crystallization inhibitor is present in an amount ranging from about 5 mg/mL to about 120 mg/mL.
7 . The stable pharmaceutical solution according to claim 1 , wherein a weight ratio of the crystallization inhibitor to the baclofen ranges from about 1:1 to 25:1.
8 . (canceled)
9 . (canceled)
10 . The stable pharmaceutical solution according to claim 1 , wherein the solution has a pH between about 3.5 to about 4.5.
11 . The stable pharmaceutical solution according to claim 1 , further comprising one or more pharmaceutically acceptable excipients selected from the group consisting of a pH modifier, a sweetening agent, a flavoring agent, a preservative, an antioxidant, a viscosity modifier, a pH adjusting agent, a buffering agent, a coloring agent, a surfactant, and mixtures thereof.
12 . The stable pharmaceutical solution according to claim 1 , further comprising a pH modifier selected from the group consisting of maleic acid, gluconic acid, glucuronic acid, and mixtures thereof.
13 . The stable pharmaceutical solution according to claim 11 , wherein the viscosity modifier is selected from the group consisting of hydroxypropyl cellulose, carboxymethyl cellulose, methylcellulose, sodium carboxymethylcellulose, carbomer, xanthan gum, maltodextrin, acacia, tragacanth, and mixtures thereof.
14 . (canceled)
15 . (canceled)
16 . The stable pharmaceutical solution according to claim 1 , wherein the solution is an aqueous solution.
17 . The stable pharmaceutical solution according to claim 1 , wherein the solution is a non-aqueous solution.
18 . The stable pharmaceutical solution according to claim 1 , wherein a level of total impurities is less than about 2% (w/w) as measured by HPLC when stored for 3 months at 40° C./75% RH.
19 . A method for managing, treating, or alleviating the signs and symptoms of spasticity resulting from multiple sclerosis, spinal cord damage or spinal cord disease in a patient by orally administering a therapeutically effective amount of the stable pharmaceutical solution according to claim 1 .
20 . The method of claim 19 , wherein the patient is a pediatric or a geriatric patient.
21 . A stable pharmaceutical solution comprising:
a) 2 mg/mL or more baclofen;
b) at least one crystallization inhibitor; and
c) at least one pharmaceutically acceptable liquid vehicle;
wherein the crystallization inhibitor is selected from the group consisting of polyvinylpyrrolidone (PVP), hydroxypropyl methyl cellulose (HPMC), hydroxyethyl cellulose (HEC), xylitol, and mixtures thereof,
wherein the solution is in the form of a ready-to-use or a ready-to-administer stable solution that is suitable for oral administration to a subject in need thereof,
wherein the solution does not contain cyclodextrin or cyclodextrin derivatives, and
wherein a weight ratio of the crystallization inhibitor to the baclofen ranges from about 1:1 to 25:1.
22 . The stable pharmaceutical solution according to claim 21 , wherein the crystallization inhibitor is hydroxypropyl methyl cellulose (HPMC) having a viscosity of 3 cps or less.
23 . The stable pharmaceutical solution according to claim 22 , wherein the stable pharmaceutical solution comprises xanthan gum, the baclofen is present at a concentration of about 5 mg/mL to about 10 mg/mL, the crystallization inhibitor is HPMC in an amount ranging from about 1 mg/m to about 200 mg/mL, and the stable pharmaceutical solution has a pH between about 3.5 to about 4.5.
24 . A stable pharmaceutical solution comprising:
a) 2 mg/mL or more baclofen;
b) at least one crystallization inhibitor; and
c) at least one pharmaceutically acceptable liquid vehicle;
wherein the crystallization inhibitor comprises hydroxypropyl methyl cellulose (HPMC) in combination with at least one additional crystallization inhibitor selected from the group consisting of polyvinylpyrrolidone (PVP), hydroxyethyl cellulose (HEC), xylitol, and mixtures thereof,
wherein the solution is in the form of a ready-to-use or a ready-to-administer stable solution that is suitable for oral administration to a subject in need thereof, and
wherein the solution does not contain cyclodextrin or cyclodextrin derivatives.
25 . The stable pharmaceutical solution of claim 24 , wherein the crystallization inhibitor comprises HPMC and xylitol.